**Supplemental Table S6. Adverse events of special interest (patients treated with spartalizumab)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Preferred Term, *n* (%)** | **Spartalizumab 400 mg Q4W*****N* = 82** | **Crossover to Spartalizumab****400 mg Q4W*****N* = 25** | **All Spartalizumab *N* = 107** |
| **All Grades** | **Grade ≥ 3** | **All Grades** | **Grade ≥ 3** | **All Grades** | **Grade ≥ 3** |
| Colitis | 6 (7.3) | 1 (1.2) | 1 (4.0) | 0 | 7 (6.5) | 1 (0.9) |
| Endocrinopathies |  |  |  |  |  |  |
| Hyperthyroidism | 5 (6.1) | 0 | 0 | 0 | 5 (4.7) | 0 |
| Hypophysitis | 4 (4.9) | 0 | 0 | 0 | 4 (3.7) | 0 |
| Hypothyroidism | 12 (14.6) | 0 | 3 (12.0) | 0 | 15 (14.0) | 0 |
| Thyroid dysfunction | 13 (15.9) | 0 | 3 (12.0) | 0 | 16 (15.0) | 0 |
| Type 1 diabetes mellitus | 4 (4.9) | 0 | 0 | 0 | 4 (3.7) | 0 |
| Hepatitis | 2 (2.4) | 1 (1.2) | 0 | 0 | 2 (1.9) | 1 (0.9) |
| Infusion reaction | 1 (1.2) | 0 | 0 | 0 | 1 (0.9) | 0 |
| Investigations |  |  |  |  |  |  |
| Liver enzyme increase | 19 (23.2) | 5 (6.1) | 3 (12.0) | 0 | 22 (20.6) | 5 (4.7) |
| Pancreatic enzymes increased | 1 (1.2) | 0 | 0 | 0 | 1 (0.9) | 0 |
| Nephritis | 5 (6.1) | 1 (1.2) | 2 (8.0) | 0 | 7 (6.5) | 1 (0.9) |
| Other immune-mediated events |  |  |  |  |  |  |
| Demyelination | 1 (1.2) | 0 | 0 | 0 | 1 (0.9) | 0 |
| Muscular disorder | 1 (1.2) | 0 | 0 | 0 | 1 (0.9) | 0 |
| Pneumonitis | 4 (4.9) | 0 | 2 (8.0) | 1 (4.0) | 6 (5.6) | 1 (0.9) |
| Rash | 26 (31.7) | 1 (1.2) | 7 (28.0) | 0 | 33 (30.8) | 1 (0.9) |
| A patient with multiple severity grades for an AE was only counted under the maximum grade.AE, adverse event; Q4W, every 4 weeks. |